United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for AEON Biopharma, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -901.45% | 279.14% | 73.62% | 42.4% | 29.78% | 22.95% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -901.45% | -966.77% | - | - | - | - |
| Total Assets | $5,560.00K | $2,554.00K | $2,554.00K | $2,554.00K | $2,554.00K | $2,554.00K |
| Net Income | -$39,222.00K | -$39,222.00K | -$39,222.00K | -$39,222.00K | -$39,222.00K | -$39,222.00K |
| Sector average | $125,199.97K | -$3,170,058.36K | -$23,486,545.34K |
| -$23,692,765.65K |
| -$23,918,648.68K |
| -$24,600,837.95K |